HOME >> MEDICINE >> NEWS
Targeted therapy shows significant benefits over standard treatment for advanced kidney cancer

ATLANTA According to a new study, the drug sunitinib malate (Sutent) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.

"This drug has shown more activity as a single agent against advanced kidney cancer than any other drug I've studied in the past 15 years," said the study's lead author Robert J. Motzer, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC). "I continue to be encouraged by its effectiveness in treating patients with this aggressive disease," said Dr. Motzer, who is a leader in the treatment of kidney cancer and conducted the earliest clinical trials on sunitinib (initially referred to as SU11248).

Interferon-alpha (IFN-) is one of the standard treatments for advanced kidney cancer, however only about 15 percent of patients respond to this immunotherapy. Sunitinib targets receptors on kidney cancer cells that may play a role in tumor growth and the development of blood vessels that feed a tumor. Previous clinical trials, also led by Dr. Motzer, showed that sunitinib caused some renal cell cancers to shrink, but this study is the first to demonstrate its effectiveness as a first-line therapy compared with standard cytokine therapy with IFN-.

The current randomized trial included 750 patients over the age of 60, half of whom were treated with a six-week cycle of sunitinib and half of whom were treated with a six-week cycle of the current treatment standard, IFN-. The primary endpoint of the trial was a comparison of progression-free survival between sunitinib and IFN- as assessed by independent third-party review. The median progression-free survival for treatment with sunitinib was 11 months, compared with 5 months following treatment with IFN-. This outcome was statistical
'"/>

Contact: Maria Connizzo
mediastaff@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
4-Jun-2006


Page: 1 2

Related medicine news :

1. Targeted, oral agent Enzastaurin shows favorable results
2. Targeted initiatives can encourage people to walk more
3. Targeted nanoparticles incorporating siRNA offer promise for cancer treatment
4. Targeted cancer drugs may work by disrupting balance of cellular signals
5. Targeted melanoma education of high risk groups improves screening
6. Targeted lymph node examination improves staging of colon cancer
7. Targeted cancer drug combined with low-dose chemotherapy shrinks tumors, slows ovarian cancer
8. Chemotherapy with bevacizumab increases risk of blood clots in arteries
9. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
10. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
11. Hormone therapy offers new hope for ovarian cancer patients

Post Your Comments:
(Date:11/21/2014)... 2014 Body Well Therapy, a leading provider ... Spafinder massage gift cards and gift certificates ... in all service areas including throughout Florida and the DC ... to the spa at all to redeem your Spafinder massage ... Well. "We may not be able to transport all of ...
(Date:11/21/2014)... 2014 (HealthDay News) -- The cost of diabetes care ... recent years, climbing to more than $322 billion annually, ... cost were seen with prediabetes care, which have risen ... percent, the researchers added. In 2012, excess medical ... than $1,000 for every American. That total includes $244 ...
(Date:11/21/2014)... 21, 2014 (HealthDay News) -- Scientists say they,ve mapped the ... from a British man,s brain, in hopes it might help ... 21 in the journal Genome Biology , the tapeworm ... of Chinese ethnicity. "This infection is so rare worldwide ... not diagnosed ... until the worm was pulled out from ...
(Date:11/21/2014)... MLF Biotech, Inc. has developed a ... Probiotics for Pets helps maintain digestive health and can ... intestinal flora after it experiences a period of stress, ... for Pets is a proprietary blend of pure probiotics ... active bacteria strains that are safe and effective for ...
(Date:11/21/2014)... Mo (PRWEB) November 21, 2014 ... the Get With The Guidelines®–Heart Failure Gold-Plus Quality ... outlined by the American Heart Association/American College of ... heart failure patients. , Get With The Guidelines–Heart ... hospital teams provide the most up-to-date, research-based guidelines ...
Breaking Medicine News(10 mins):Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2Health News:MLF Biotech Introduces Liv-Pro Probiotics for Pets 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4
(Date:11/21/2014)... Inc. (NASDAQ: DEPO ) today announced that it will ... Conference in New York City . ... am EST (5:00 am PST) on Tuesday December 2, 2014.  The ... the Investor Relations page of the Depomed website at www.depomed.com ... days on the company,s website. About Depomed ...
(Date:11/21/2014)... Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... previously announced underwritten public offering of $50,000,000 of shares ... registration statement. The offering will consist of 49,751,244 shares ... $1.005 per share.  Lexicon has also granted the underwriters ... shares of common stock.  All of the shares in ...
(Date:11/18/2014)... LOS ANGELES , Nov. 18, 2014 /PRNewswire/ ... technology development, patient engagement and study recruitment – ... platform, called Sangre, to help Pfizer Inc. find ... Pain (CIP) and their family members to participate ... help potentially identify DNA mutations and hopefully aid ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2
Cached News: